Abstract
Personalized medicine and pharmacogenomics are inextricably linked.
Pharmacogenomics is the use of genetic variations (such as SNPs, gene
expression variability, or other molecular signatures) to understand and
correlate with differential response to pharmaceutical agents (drugs).
Pharmacogenomics can be deployed clinically to stratify patients into
responders and non-responders and this practice is termed personalized
medicine. The purpose of this TriMark Publications report is to describe the
specific market segment of the diagnostics market called personalized
medicine. To frame the context of current approaches, pharmacogenomics seeks
to identify and validate the signature(s) of molecular analytes and these are
converted to assays using the tools of molecular diagnostics. The deployment
of these molecular diagnostics assays on defining and targeting patient
populations is the domain of personalized medicine. This study includes all of
the generally-accepted imaging activities that are currently used in
personalized medicine, including pharmacogenomics, genomics and theranostics.
It examines associated clinical market segments in which personalized medicine
has taken a prominent role including cancer treatment, cardiology and
neurology markets.
View Cart
